CN100522172C - 非镇静巴比土酸盐化合物在制备神经保护剂中的用途 - Google Patents

非镇静巴比土酸盐化合物在制备神经保护剂中的用途 Download PDF

Info

Publication number
CN100522172C
CN100522172C CNB2006100813267A CN200610081326A CN100522172C CN 100522172 C CN100522172 C CN 100522172C CN B2006100813267 A CNB2006100813267 A CN B2006100813267A CN 200610081326 A CN200610081326 A CN 200610081326A CN 100522172 C CN100522172 C CN 100522172C
Authority
CN
China
Prior art keywords
use according
pharmaceutical composition
mammal
cerebral ischemia
neuroprotection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2006100813267A
Other languages
English (en)
Chinese (zh)
Other versions
CN1872067A (zh
Inventor
丹尼尔·A·莫罗斯
巴里·莱维特
阿夫拉汉姆·亚科比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taro Pharmaceutical Industries Ltd
Original Assignee
Taro Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharmaceutical Industries Ltd filed Critical Taro Pharmaceutical Industries Ltd
Publication of CN1872067A publication Critical patent/CN1872067A/zh
Application granted granted Critical
Publication of CN100522172C publication Critical patent/CN100522172C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB2006100813267A 2000-07-26 2001-07-26 非镇静巴比土酸盐化合物在制备神经保护剂中的用途 Expired - Fee Related CN100522172C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22167200P 2000-07-26 2000-07-26
US60/221,672 2000-07-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB018151426A Division CN1329032C (zh) 2000-07-26 2001-07-26 非镇静巴比土酸盐化合物用作神经保护剂

Publications (2)

Publication Number Publication Date
CN1872067A CN1872067A (zh) 2006-12-06
CN100522172C true CN100522172C (zh) 2009-08-05

Family

ID=22828824

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB2006100813267A Expired - Fee Related CN100522172C (zh) 2000-07-26 2001-07-26 非镇静巴比土酸盐化合物在制备神经保护剂中的用途
CNB018151426A Expired - Fee Related CN1329032C (zh) 2000-07-26 2001-07-26 非镇静巴比土酸盐化合物用作神经保护剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB018151426A Expired - Fee Related CN1329032C (zh) 2000-07-26 2001-07-26 非镇静巴比土酸盐化合物用作神经保护剂

Country Status (13)

Country Link
EP (1) EP1311270B1 (enExample)
JP (1) JP5047442B2 (enExample)
CN (2) CN100522172C (enExample)
AT (1) ATE383159T1 (enExample)
AU (2) AU8077801A (enExample)
BR (1) BR0112775A (enExample)
CA (1) CA2416535C (enExample)
DE (1) DE60132337T2 (enExample)
ES (1) ES2300349T3 (enExample)
IL (3) IL154060A0 (enExample)
MX (1) MXPA03000824A (enExample)
PT (1) PT1311270E (enExample)
WO (1) WO2002007729A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093820A (en) 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1311270B1 (en) * 2000-07-26 2008-01-09 Taro Pharmaceutical Industries Limited Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
CN1896084A (zh) * 2002-01-30 2007-01-17 塔罗制药工业有限公司 非镇静性巴比土酸衍生物
CN102283821A (zh) * 2002-10-11 2011-12-21 巴克斯特国际公司 含有卤化挥发性麻醉药的制剂在制备通过肠外给药用于治疗组织具有缺血事件的患者的制剂中的应用
CN100502871C (zh) * 2002-12-11 2009-06-24 塔罗制药工业有限公司 巴比土酸衍生物在制备用于治疗运动障碍的药物中的应用
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
RU2370266C2 (ru) * 2007-12-21 2009-10-20 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по высокотехнологичной медицинской помощи" Способ общего обезболивания
WO2013038427A1 (en) * 2011-09-12 2013-03-21 Council Of Scientific & Industrial Research ARYLATED β-DICARBOIMYL COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
CN113640512B (zh) 2015-10-05 2024-12-31 北卡罗来纳-查佩尔山大学 用于多路测定的解码方法及相关流体设备、试剂盒和固体支持物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
US4833148A (en) * 1987-04-09 1989-05-23 Washington University Method of using alkenyl- or alkynyl-substituted thiobarbiturates to reduce neurotoxic injury
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
EP1311270B1 (en) * 2000-07-26 2008-01-09 Taro Pharmaceutical Industries Limited Non-sedating barbiturate compounds as neuroprotective agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Method for the determination of 5,5-dimethoxymethyl-5,5-diphenyl barbituric acid in plasma byhigh-performance liquid chromatography. Thacker D. L. et al.Jou. of Chromatography B,Vol.710 No.1. 1998 *
The effects of 5,5 diphenyl barbituric acid onexperimentalseizures and anti convulsant activity. Raines et al.Epilepsia,Vol.16 No.4. 1975 *

Also Published As

Publication number Publication date
IL154060A (en) 2013-05-30
AU8077801A (en) 2002-02-05
ATE383159T1 (de) 2008-01-15
BR0112775A (pt) 2003-12-30
WO2002007729A1 (en) 2002-01-31
JP5047442B2 (ja) 2012-10-10
DE60132337T2 (de) 2009-02-12
CA2416535C (en) 2010-11-16
JP2004517808A (ja) 2004-06-17
IL154060A0 (en) 2003-07-31
MXPA03000824A (es) 2004-11-01
CA2416535A1 (en) 2002-01-31
IL165017A0 (en) 2005-12-18
WO2002007729A9 (en) 2002-08-08
ES2300349T3 (es) 2008-06-16
CN1872067A (zh) 2006-12-06
PT1311270E (pt) 2008-04-15
CN1461219A (zh) 2003-12-10
DE60132337D1 (de) 2008-02-21
EP1311270A4 (en) 2006-04-12
EP1311270A1 (en) 2003-05-21
AU2001280778B2 (en) 2004-09-02
CN1329032C (zh) 2007-08-01
EP1311270B1 (en) 2008-01-09
HK1100814A1 (en) 2007-09-28

Similar Documents

Publication Publication Date Title
CN100522172C (zh) 非镇静巴比土酸盐化合物在制备神经保护剂中的用途
US8158639B2 (en) Non-sedating barbiturate compounds as neuroprotective agents
PT1505973E (pt) Combinações para o tratamento de mieloma múltiplo
TW200418460A (en) Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
IL268125B2 (en) Pridopidine for the treatment of fragile x syndrome
AU2001280778A1 (en) Non-sedating barbiturate compounds as neuroprotective agents
US6939873B2 (en) Non-sedating barbituric acid derivatives
KR20190087572A (ko) 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
JP2024149602A (ja) 境界性パーソナリティ障害の処置方法
CA2471436C (en) Non-sedating barbituric acid derivatives
AU2004229086B2 (en) Non-sedating barbiturate compounds as neuroprotective agents
HK1100814B (en) Use Of A Salt Of Diphenyl Barbituric Acid In Preparing Neuroprotective Agents
JP7535797B2 (ja) 化合物バフィデムスタット（ｖａｆｉｄｅｍｓｔａｔ）などｋｄｍ１ａ阻害剤を使用した注意欠陥多動性障害の処置方法
AU2007200460B2 (en) Non-sedating barbiturate compounds as neuroprotective agents
EP1905441A2 (en) Non-sedating barbiturate compounds as neuroprotective agents
US20240376098A1 (en) Methods of treatment using bcn057, bcn077 and analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1100814

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1100814

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090805

Termination date: 20140726

EXPY Termination of patent right or utility model